These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 15658468)
1. [Relationship between aneuploidy of chromosome 17 and amplification of HER-2/neu gene in the different histological type of breast cancer]. Kuroso K; Ueda Y; Mori Y Rinsho Byori; 2004 Nov; 52(11):897-9. PubMed ID: 15658468 [TBL] [Abstract][Full Text] [Related]
2. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542 [TBL] [Abstract][Full Text] [Related]
3. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898 [TBL] [Abstract][Full Text] [Related]
4. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175 [TBL] [Abstract][Full Text] [Related]
5. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736 [TBL] [Abstract][Full Text] [Related]
6. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Bartlett JM; Campbell FM; Mallon EA Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769 [TBL] [Abstract][Full Text] [Related]
7. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
8. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Varshney D; Zhou YY; Geller SA; Alsabeh R Am J Clin Pathol; 2004 Jan; 121(1):70-7. PubMed ID: 14750243 [TBL] [Abstract][Full Text] [Related]
9. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552 [TBL] [Abstract][Full Text] [Related]
10. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Afify AM; Werness BA; Mark HF Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445 [TBL] [Abstract][Full Text] [Related]
11. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Bhargava R; Lal P; Chen B Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048 [TBL] [Abstract][Full Text] [Related]
12. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Mezzelani A; Alasio L; Bartoli C; Bonora MG; Pierotti MA; Rilke F; Pilotti S Br J Cancer; 1999 May; 80(3-4):519-25. PubMed ID: 10408862 [TBL] [Abstract][Full Text] [Related]
13. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Ma Y; Lespagnard L; Durbecq V; Paesmans M; Desmedt C; Gomez-Galdon M; Veys I; Cardoso F; Sotiriou C; Di Leo A; Piccart MJ; Larsimont D Clin Cancer Res; 2005 Jun; 11(12):4393-9. PubMed ID: 15958623 [TBL] [Abstract][Full Text] [Related]
14. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605 [TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446 [TBL] [Abstract][Full Text] [Related]
16. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995 [TBL] [Abstract][Full Text] [Related]
17. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens. Lin F; Shen T; Prichard JW Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744 [TBL] [Abstract][Full Text] [Related]
18. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. Lal P; Salazar PA; Ladanyi M; Chen B J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205 [TBL] [Abstract][Full Text] [Related]